Increased Activation of the Haemostatic System in Men at High Risk of Fatal Coronary Heart Disease

Summary

The haemostatic system was examined in 2951 men aged 50 to 61 years, clinically free of cardiovascular disease, who were ranked according to a risk score for fatal coronary heart disease (CHD). Risk was judged from their serum cholesterol concentration, systolic blood pressure, body mass index and smoking habit. The status of the factor VH-tissue factor pathway was estimated from the plasma levels of factor VII coagulant activity, factor VII antigen and activated factor VII. Activation of factor IX was assessed from the plasma concentration of factor IX activation peptide. Activity within the common pathway was measured as the plasma concentrations of prothrombin fragment 1+2 and fibrinopeptide A. All 6 markers of haemostatic status were positively and statistically significantly associated with risk, providing further evidence for a hypercoagulable state in men at high risk for fatal CHD. Plasma fibrinogen and serum triglyceride concentrations were also graded positively with risk.

• References

• 1 Grundy SM, Greenland P, Herd A, Huebsch JA, Jones RJ, Mitchell JH, Schlant RC. Cardiovascular and risk factor evaluation of healthy American adults. A statement for physicians by an Ad Hoc Committee appointed by the Steering Committee, American Heart Association. Circulation 1987; 75: 1340A-1362A
• 2 Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Eng J Med 1984; 310: 1137-1140
• 3 De Wood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303: 897-902
• 4 Fuster V, Chesebro JH. Mechanism of unstable angina. N Engl J Med 1986; 315: 1023-1025
• 5 Gurfinkel E, Altman R, Scazziota A, Rouvier J, Mautner B. Importance of thrombosis and thrombolysis in silent ischaemia: comparison of patients with acute myocardial infarction and unstable angina. Br Heart J 1994; 71: 151-155
• 6 Brozovic M, Stirling Y, Harricks C, North WRS, Meade TW. Factor VII in an industrial population. Br J Haematol 1974; 28: 381-391
• 7 Balleisen L, Bailey J, Epping P-H, Schulte H, van de Loo J. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population: 1. Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill-using, and menopause. Thromb Haemost 1985; 54: 475-479
• 8 Ruddock V, Meade TW. Factor VII activity and ischaemic heart disease: fatal and non-fatal events. Q J Med 1994; 8: 403-406
• 9 Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler Thromb 1994; 14: 54-59
• 10 Bauer KA, Kass BL, ten Cate H, Hawiger JJ, Rosenberg RD. Factor IX is activated in vivo by the tissue factor mechanism. Blood 1990; 76: 731-736
• 11 Bauer KA, Weiss LM, Sparrow D, Vokonas PS, Rosenberg RD. Aging -associated changes in indices of thrombin generation and protein C activation in humans. Normative Aging Study. J Clin Invest 1987; 80: 1527-1534
• 12 Hursting MJ, Stead AG, Crout FV, Horvath BZ, Moore BM. Effects of age, race, sex, and smoking on prothrombin fragment 1.2 in a healthy population. Clin Chem 1993; 39: 683-686
• 13 Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C, Man-nucci PM, Rosenberg RD. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994; 90: 61-68
• 14 Rose GA. The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. Bull WHO 1962; 27: 645-658
• 15 Medical Research Council’s Committee on Research on Chronic Bronchitis. Questionnaire on Respiratory Symptoms. Publications Group, Medical Research Council, 20 Park Crescent, London WIN 4AL.
• 16 Prineas RJ, Crow RS, Blackburn H. The Minnesota Code Manual of Electrocardiographic Findings. Standards and Procedures for Measurement and Classification. Boston: John Wright, PSC Inc; 1982
• 17 Miller GJ, Bauer KA, Barzegar S, Foley AJ, Mitchell JP, Cooper JA, Rosenberg RD. The effects of quality and timing of venepuncture on markers of blood coagulation in healthy middle-aged men. Thromb Haemost 1995; 73: 82-86
• 18 Miller GJ, Stirling Y, Esnouf MP, Heinrich J, van de Loo J, Kienast J, Wu KK, Morrissey JH, Meade TW, Martin JC, Imeson JD, Cooper JA, Finch A. Factor VH-deficient substrate plasmas depleted of protein C raise the sensitivity of the factor VII bio-assay to activated factor VII: an international study. Thromb Haemost 1994; 71: 38-48
• 19 Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-744
• 20 von Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-246
• 21 Teitel JM, Bauer KA, Lau HK, Rosenberg RD. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1+2 fragment and thrombin-antithrombin complex. Blood 1982; 59: 1086-1097
• 22 Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WRS, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; ii: 533-537
• 23 Liu K, Stamler J, Dyer A, McKeever J, McKeever P. Statistical methods to assess and minimize the role of intra-individual variability in obscuring the relationship between dietary lipids and serum cholesterol. J Chron Dis 1978; 31: 399-416
• 24 Hoffmann C, Shah A, Sodums M, Hultin MB. Factor VII activity state in coronary artery disease. J Lab Clin Med 1988; 111: 475-481
• 25 Hoffmann CJ, Miller RH, Lawson WE, Hultin MB. Elevation of factor VII activity and mass in young adults at risk of ischemic heart disease. J Am Coll Cardiol 1989; 14: 941-946
• 26 Suzuki T, Yamauchi K, Matsushita T, Furumichi T, Furui H, Tsuzuki J, Saito H. Elevation of factor VII activity and mass in coronary artery disease of varying severity. Clin Cardiol 1991; 14: 731-736
• 27 Moor E, Silveira A, van’t Hooft F, Suontaka AM, Eriksson P, Blomback M, Hamsten A. Coagulation factor VII mass and activity in young men with myocardial infarction at a young age. Role of plasma lipoproteins and factor VII genotype. Arterioscler Thromb Vase Biol 1995; 15: 655-664
• 28 Kario K, Miyata T, Sakata T, Matsuo T, Kato H. Fluorogenic assay of activated factor VII. Plasma factor Vila levels in relation to arterial cardiovascular diseases in Japanese. Arterioscler Thromb 1994; 14: 265-274
• 29 Miller GJ, Martin JC, Mitropoulos KA, Reeves BEA, Thompson RC, Meade TW, Cooper JA, Cruickshank JK. Plasma factor VII is activat by postprandial triglyceridaemia, irrespective of dietary fat compositk. Atherosclerosis 1991; 86: 163-171
• 30 Silveira A, Karpe F, Blomback M, Steiner G, Walldius G. Hamsten Activation of coagulation factor VII during alimentary lipemia. Arterioscler Thromb 1994; 14: 60-69
• 31 Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JO. Hemostatic factors and the risk of myocardial infarction or sudden death patients with angina pectoris. N Engl J Med 1995; 332: 635-641
• 32 Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tiss factor in the normal vessel wall and in the atherosclerotic plaque. Proc Ni Acad Sci USA 1989; 86: 2839-2843
• 33 Grabowski EF, Zuckerman DB, Nemerson Y. The functional expression tissue factor by fibroblasts and endothelial cells under flow conditions. Blood 1993; 81: 3265-3270
• 34 Edwards RL, Rickies FR, Bobrove AM. Mononuclear cell tissue factc cell of origin and requirements for activation. Blood 1979; 54: 359-370
• 35 Nossel HL, Yudelman I, Canfield RE, Butler VP, Spanondis K, Wilner GD, Qureshi GD. Measurement of fibrinopeptide A in human blood. J Cl Invest 1974; 54: 43-53
• 36 Lowe GDO, Wood DA, Douglas JT, Riemersma RA, Macintyre CO, Takase T, Tuddenham EGD, Forbes CD, Elton RA, Oliver MF. Relatioi ships of plasma viscosity, coagulation and fibrinolysis to coronary ris factors and angina. Thromb Haemost 1991; 65: 339-343
• 37 Miller GJ, Walter SJ, Stirling Y, Thompson SG, Esnouf MP. Assay of factor VII by two techniques: evidence for increased conversion of VII to αVII_a in hyperlipidaemia, with possible implications for ischaemic hea disease. Br J Haematol 1985; 59: 249-258
• 38 Bruckert E, Carvalho de SousaJ, Giral P, Soria C, Chapman MJ, Caen de Gennes J-L. Interrelationship of plasma triglyceride and coagulant fact( VII levels in normotriglyceridemic hypercholesterolemia. Atheroscleros 1989; 75: 129-134
• 39 Mitropoulos KA, Miller GJ, Watts GF, Durrington PN. Lipolysis of triglj ceride-rich lipoproteins activates coagulant factor XII: a study in famili; lipoprotein-lipase deficiency. Atherosclerosis 1992; 95: 119-125
• 40 Mitropoulos KA, Esnouf MP. Turnover of factor X and prothrombin i rabbits fed on a standard or cholesterol-supplemented diet. Biochem J 1987; 244: 263-269
• 41 Bauer KA. Laboratory markers of coagulation activation. Arch Pathol La Med 1993; 117: 71-77
• 42 Wilkes HW, Meade TW, Barzegar S, Foley AJ, Hughes LO, Bauer KA, Rosenberg RD, Miller GJ. Gemfibrozil reduces plasma prothrombin fragmer F₁₊₂ concentration, a marker of coagulability, in patients with coronar heart disease. Thromb Haemost 1992; 67: 503-506
• 43 Avellone G, Di Garbo V, Cordova R, Panno AV, Raneli G, De Simone F, Bompiani GD. Fibrinolytic effect of gemfibrozil versus placebo admin istration in response to venous occlusion. Fibrinolysis 1993; 7: 416-421
• 44 Brown BG, Zhao X-Q, Sacco DE, Albers JJ. Lipid lowering and plaqui regression. Circulation 1993; 87: 1781-1791
• 45 Mitropoulos KA, Reeves BEA, Miller GJ. The activation of factor VII ii citrated plasma by charged long-chain saturated fatty acids at the interfaci of large triglyceride-rich lipoproteins. Blood Coag Fibrinol 1993; 4: 943-951
• 46 Poller L, MacCallum PK, Thomson JM, Kerns W. Reduction in factor VI coagulant activity (VIIc), a risk factor for ischaemic heart disease, by fixec dose warfarin: a double blind crossover study. Br Heart J 1990; 63: 231-233
• 47 Bauer KA, Rosenberg RD. The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation. Blood 1987; 70: 343-350
• 48 Meade TW, Miller GJ. Combined use of aspirin and warfarin in primary prevention of ischemic heart disease in men at high risk. Am J Cardio 1995; 75: 23B-26B